Orchard Therapeutics

Orchard Therapeutics develops ex vivo autologous gene therapies based on its hematopoietic stem cell (HSC) gene therapy platform. Its stated focus is severe genetic diseases, with programs named in the input for ADA-SCID, metachromatic leukodystrophy (MLD) and mucopolysaccharidosis type IIIA and IIIB. The company also acquired Strimvelis, an ex vivo gene therapy approved by the European Medicines Agency for ADA-SCID, which the website notes is not approved in the US.

The input names patients and families affected by severe genetic diseases, along with physicians and treatment centers, as the people it works with on diagnosis, education and access to therapy. It does not describe its revenue model in detail. The website states that Orchard was recently acquired by Kyowa Kirin.

Orchard states it was founded in September 2015 and opened its first office in London in January 2016, later moving to larger space. Its U.S. operations began in Foster City, California in October 2016 and later moved to Menlo Park. The current job listings include roles in London, including clinical operations, pharmacovigilance and regulatory, and a U.S. medical affairs role in Boston, Massachusetts, plus a remote regulatory science role.

Product: HSC gene therapy platform and Strimvelis, an EU-approved ex vivo autologous gene therapy for ADA-SCID.